Skip to main content
. 2013 Mar;98(3):404–408. doi: 10.3324/haematol.2012.067959

Figure 3.

Figure 3.

Ruxolitinib inhibits colony growth of JAK2 rearranged or amplified primary cells. (A) Colony numbers of samples from 3 patients with JAK2 rearrangements or amplification, 7 healthy controls and 3 CML controls were counted at Days 7 and 14. The y-axis response index is the mean reduction in Days 7 and 14 colony counts in ruxolitinib-treated methylcellulose cultures compared to untreated cultures for all ruxolitinib concentrations. (B) Comparison of JAK2 cases and healthy controls showed a progressive reduction in colony numbers with increasing ruxolitinib concentrations. In cases 1 (C) and 2 (D) a subset of colonies were plucked on Day 14 for JAK2 FISH analysis allowing the size of the JAK2-rearrangement positive and negative fractions to be estimated. In both cases, the number of JAK2-rearrangement positive colonies fell at lower ruxolitinib concentrations than JAK2-rearrangement negative colonies.